DSM Nutritional Products Contracts Ludesi for 2D Gel Image Analysis
News Feb 22, 2007
DSM has contracted Ludesi for image analysis of two-dimensional protein gels (2D gels), the basic workhorse in the field of proteomics.
DSM tested Ludesi’s image analysis service thoroughly and concluded that Ludesi’s offering provided increased quality and reproducibility.
“Thanks to our agreement with Ludesi we have been able to debottleneck the protein quantification step in our high-throughput 2D-gel-based proteomics platform. We get accurate relative quantitative data for a considerably larger number of spots than we could before,” comments Dr. Isabelle Maillet at DSM Nutritional Products in Basel.
Dr. Maillet continued, “this improvement is of great value for an in-depth understanding of the metabolism of the microbes we are working on and thus for further engineering of biotechnological production strains.”
Ludesi has industrialized and centralized image and data analysis of 2D gels using a special quality-controlled image analysis process and in-house technically advanced software. The analysis process can enable scientists to get a high level of accuracy compared to using commercially available software.
“It is rewarding that Ludesi’s technology aids the professional scientists at DSM Nutritional Products to push the limits of their world-leading research further. I have the deepest respect for their work and we look forward to working together in the years to come,” comments Ola Forsstrom-Olsson, CEO at Ludesi.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.